NYSE:PRGO Perrigo Q4 2024 Earnings Results & Report $15.33 +0.27 (+1.79%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Perrigo beat analyst earnings expectations but missed on revenue in its Q4 2024 results, released February 27, 2025. The company reported EPS of $0.93 versus the $0.92 consensus estimate, while revenue of $1.14 billion fell short of the $1.20 billion estimate by $57.66 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 27, 2025TimeAfter Market ClosesConference Call4:00 PM ET Perrigo EPS ResultsActual EPS$0.93Consensus EPS $0.92Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersPerrigo Revenue ResultsActual Revenue$1.14 billionExpected Revenue$1.20 billionBeat/MissMissed by -$57.66 millionYoY Revenue GrowthN/AUpcoming EarningsPerrigo's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Perrigo Q4 2024 Earnings FAQ Did Perrigo beat earnings estimates for Q4 2024? Perrigo (NYSE:PRGO) reported earnings of $0.93 per share for Q4 2024, beating the consensus estimate of $0.92. The report was announced on Thursday, February 27, 2025. What was Perrigo's revenue for Q4 2024? Perrigo reported revenue of $1.14 billion for Q4 2024, against a consensus estimate of $1.20 billion. When is Perrigo's next earnings date? Perrigo's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Perrigo on the company's earnings history page. Perrigo Earnings HeadlinesPerrigo Co PLC (PRGO) Stock Up 3.9% and Still Undervalued -- GF Score: 60/100October 9 at 12:00 AM | gurufocus.comPerrigo may have attracted takeover interest - BetavilleOctober 9 at 7:17 PM | seekingalpha.comPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has poured billions into this firm, which may have found a solution to the growing AI energy crunch. Unlike pricey chipmakers trading at 40 times earnings, this pure-play AI energy name remains cheap and profitable. See the name and ticker behind this fast-moving story before wider attention catches on.October 12 at 1:00 AM | Monument Traders Alliance (Ad)Perrigo to Attend the Barclays Global Consumer ConferenceAugust 27, 2026 | prnewswire.comPerrigo Company plcAugust 24, 2026 | money.usnews.comThis Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.August 22, 2026 | fool.comSee More Perrigo Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email. Email Address About PerrigoPerrigo (NYSE:PRGO) (NYSE: PRGO) is a global consumer self-care company that develops, manufactures and sells over-the-counter (OTC) health and wellness products. Its portfolio includes products for pain relief, allergy and cold relief, digestive health, sleep support, skin care, women’s health and oral care. Perrigo supplies both its own brands and retailer-owned store brands. The company markets products under a range of brand names, including Compeed, ACO, ellaOne and other regional brands, while also producing private-label alternatives to widely used consumer health products. Perrigo sells through pharmacies, supermarkets, mass retailers, e-commerce channels and other healthcare outlets. Founded in 1887 in Allegan, Michigan, Perrigo has expanded from a U.S. supplier of private-label medicines into an international consumer health company. It serves customers across North America, Europe and other global markets, with operations and products tailored to regional consumer and regulatory requirements. Patrick Lockwood-Taylor has served as Perrigo’s president and chief executive officer since 2023.View Perrigo ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
